Key facts
- This page summarizes Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Apr 2026, 06:03.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 20 Apr 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- KLRA
- Reported as of
- 20 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Apr 2026, 06:03:23 UTC
- Prior SEC filing
- 16 Apr 2026
- Next SEC filing
- 06 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. /s/ Lau Kin Chun, Financial Controller, on behalf of Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 22 Apr 2026.
Change
- Previous filing in this sequence was filed on 16 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002080343
Primary reporting owner
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Relationship
- 10%+ Owner
- Address
- 7 KUNLUNSHAN RD, ECON. & TECH. DEV. ZONE, LIANYUNGANG, CHINA
- Signature
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. /s/ Lau Kin Chun, Financial Controller, on behalf of Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Signature date
- 22 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KLRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +9,477,719
- Change %
- Price
- Shares after
- 9,477,719
- Date
- 20 Apr 2026
- Ownership
- Direct
- Footnotes
- F2
KLRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,034,133
- Change %
- Price
- Shares after
- 2,034,133
- Date
- 20 Apr 2026
- Ownership
- Direct
- Footnotes
- F2
KLRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1
- Date
- 20 Apr 2026
- Ownership
- By Hengrui (USA) Ltd.
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KLRA
transaction
Derivative
Series A-2 convertible preferred stock
Conversion of derivative security
- Transaction value
- Shares
- -4,968,789
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 20 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,477,719
- Exercise price
- Footnotes
- F2
KLRA
transaction
Derivative
Series A-2 convertible non-voting preferred stock
Conversion of derivative security
- Transaction value
- Shares
- -708,814
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 20 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,034,133
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Footnote F2
The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.